ATPase family AAA domain-containing protein 2 (ATAD2): From an epigenetic modulator to cancer therapeutic target

Fu, Jiahui; Zhang, Jin; Chen, Xiya; Liu, Zhiying; Yang, Xuetao; He, Zhendan; Hao, Yue; Liu, Bo; Yao, Dahong

doi:10.7150/thno.78840

Nanotheranostics

International Journal of Biological Sciences

International Journal of Medical Sciences

Journal of Cancer

open access Global reach, higher impact

Full Text | PDF

Theranostics 2023; 13(2):787-809. doi:10.7150/thno.78840 This issue Cite

Review

ATPase family AAA domain-containing protein 2 (ATAD2): From an epigenetic modulator to cancer therapeutic target

Jiahui Fu^1,2#, Jin Zhang^3#, Xiya Chen^1,3#, Zhiying Liu^1,3, Xuetao Yang¹, Zhendan He¹, Yue Hao^3✉, Bo Liu^2✉, Dahong Yao^1✉

1. School of Pharmaceutical Sciences, Shenzhen Technology University, Shenzhen, 518118, China.
2. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
3. School of Pharmaceutical Sciences, Medical School, Shenzhen University, Shenzhen 518060, China.
^#These authors contributed equally to this work.

Citation:

Fu J, Zhang J, Chen X, Liu Z, Yang X, He Z, Hao Y, Liu B, Yao D. ATPase family AAA domain-containing protein 2 (ATAD2): From an epigenetic modulator to cancer therapeutic target. Theranostics 2023; 13(2):787-809. doi:10.7150/thno.78840. https://www.thno.org/v13p0787.htm

Other styles

Abstract

ATPase family AAA domain-containing protein 2 (ATAD2) has been widely reported to be a new emerging oncogene that is closely associated with epigenetic modifications in human cancers. As a coactivator of transcription factors, ATAD2 can participate in epigenetic modifications and regulate the expression of downstream oncogenes or tumor suppressors, which may be supported by the enhancer of zeste homologue 2. Moreover, the dominant structure (AAA + ATPase and bromine domains) can make ATAD2 a potential therapeutic target in cancer, and some relevant small-molecule inhibitors, such as GSK8814 and AZ13824374, have also been discovered. Thus, in this review, we focus on summarizing the structural features and biological functions of ATAD2 from an epigenetic modulator to a cancer therapeutic target, and further discuss the existing small-molecule inhibitors targeting ATAD2 to improve potential cancer therapy. Together, these inspiring findings would shed new light on ATAD2 as a promising druggable target in cancer and provide a clue on the development of candidate anticancer drugs.

Keywords: ATPase family AAA domain-containing protein 2 (ATAD2), Epigenetic modification, Therapeutic target, Small-molecule inhibitor, Cancer therapy, Anticancer drug

Citation styles

APA

Fu, J., Zhang, J., Chen, X., Liu, Z., Yang, X., He, Z., Hao, Y., Liu, B., Yao, D. (2023). ATPase family AAA domain-containing protein 2 (ATAD2): From an epigenetic modulator to cancer therapeutic target. Theranostics, 13(2), 787-809. https://doi.org/10.7150/thno.78840.

ACS

Fu, J.; Zhang, J.; Chen, X.; Liu, Z.; Yang, X.; He, Z.; Hao, Y.; Liu, B.; Yao, D. ATPase family AAA domain-containing protein 2 (ATAD2): From an epigenetic modulator to cancer therapeutic target. Theranostics 2023, 13 (2), 787-809. DOI: 10.7150/thno.78840.

NLM

CSE

Fu J, Zhang J, Chen X, Liu Z, Yang X, He Z, Hao Y, Liu B, Yao D. 2023. ATPase family AAA domain-containing protein 2 (ATAD2): From an epigenetic modulator to cancer therapeutic target. Theranostics. 13(2):787-809.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.